Aims
One of the three primary objectives of the Coronary Drug Project (CDP) was to develop more advanced methodology for the design and conduct of long-term, large, collaborative trials which could be applied to other such studies. Overviews of the design and methods of the CDP have been published previously, as has a detailed monograph on design, methods, and baseline results. However, these papers and monograph simply described methods used in the CDP without discussing their merits and demerits, and whether or not they should be recommended for use in future studies. An attempt has been made in this monograph to devote greater attention to those methods deemed to work well in the CDP. Methods not to be recommended for future studies are noted, with alternative approaches suggested. In some cases, CDP methods are compared and evaluated against those of other multicenter clinical trials. Methods used in more recent studies are occasionally described if deemed to represent a major improvement over CDP methods (Preface, page ix).

Contents (iii+264 pages)
Preface (Paul L Canner)
Contributors
1: Brief description of the Coronary Drug Project and other studies (Paul L Canner)
2: Evolution and funding of the Coronary Drug Project (William J Zukel)
3: Experimental design features (Paul L Canner and Christian R Klimt)
4: Organizational structure of the study (Paul L Canner, Jeremiah Stamler)
5: Role of the National Institutes of Health (William J Zukel, Max Halperin, Lawrence Friedman, Eleanor MK Darby)
6. Role and methods of the coordinating center (Curtis L Meinert, Elizabeth C Heinz, Sandra A Forman)
7. Role and methods of the central laboratory (Adrian Hainline Jr, Dayton T Miller, Alan Mather)
8. Role and methods of the ECG reading center (Ronald J Prineas, Henry Blackburn)
9. Role and methods of the drug procurement and distribution center (E Clifford Brennan)
10. Role and methods of the clinical centers (Kenneth G Berge, Charles A Laubach Jr, Richard G Hutchinson)
11. Design of data forms (Genell L Knatterud, Sandra A Forman, Paul L Canner)
12. External quality control programs (Paul L Canner, William F Krol, Sandra A Forman)
13. Monitoring of the data for evidence of adverse or beneficial treatment effects (Paul L Canner)
14. Further aspects of data analysis (Paul L Canner)
15. Closing down the study (William F Krol)
16. Impact of the Coronary Drug Project findings on clinical practice (Lawrence Friedman, Nanette K Wenger, Genell L Knatterud)
Appendix: Coronary Drug Project Personnel

Authors
The editor is Paul L Canner PhD (University of Maryland, Department of Epidemiology and Preventive Medicine, Division of Clinical Investigation, Baltimore, MD, USA). The authors
are Kenneth G Berge MD (Mayo Clinic Rochester, MN, USA); Henry Blackburn MD (University of Minnesota, Minneapolis, MN, USA); E Clifford Brennan (retired from USPHS Supply Service Center, Perry Point, MD, USA); Eleanor MK Darby PhD (retired from National Heart, Lung, and Blood Institute, Bethesda, USA); Sandra A Forman (University of Maryland, Baltimore, MD, USA); Lawrence M Friedman MD (National Heart, Lung, and Blood Institute, Bethesda, MD, USA); Adrian Hainline Jr PhD (Clinical Chemistry Standardization Section, Metabolic Biochemistry Branch, Clinical Chemistry Division, Center for Environmental Health, Centers for Disease Control, Atlanta, GA, USA); Max Halperin PhD (George Washington University, Bethesda, MD, USA); Elizabeth C Heinz (University of Maryland, Baltimore, MD, USA); Richard G Hutchinson MD (University Hospital, Jackson, MS, USA); Christian R Klimt MD, DrPH (Maryland Medical Research Institute, Baltimore, MD, USA); Genell L Knatterud PhD (University of Maryland, Department of Epidemiology and Preventive Medicine, Division of Clinical Investigation, Baltimore, MD, USA); William F Krol PhD (Maryland Medical Research Institute, Baltimore, MD, USA); Charles A Laubach Jr MD (Geisinger Medical Center, Danville, PA, USA); Alan Mather PhD (retired from Centers for Disease Control, Atlanta, GA, USA); Curtis L Meinert PhD (Johns Hopkins School of Hygiene and Public Health, Department of Epidemiology, Baltimore, MD, USA); Dayton T Miller PhD (Centers for Disease Control, Atlanta, GA, USA); Ronald J Prineas MB, BS, PhD (University of Minnesota, College of Medical Science, School of Public Health, Laboratory of Physiological Hygiene, Minneapolis, USA); Jeremiah Stamler MD (Northwestern University, Chicago, IL, USA); Nanette K Wenger MD (Emory School of Medicine, Atlanta, GA, USA); and, William J Zukel MD (Associate Director, Scientific Program, Division of Heart and Vascular Disease, National Heart, Lung and Blood Institute, Bethesda, MD, USA).